News Sentiment

XOMA sentiment intelligence

XOMA Royalty Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 40.17 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy

73/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-9.2% over one week, -4.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy 73/100 classification
One-week reaction -9.2% Price reacting lower
Trend fit Trend active -4.1% over four weeks
Fair value 50.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 11
GlobeNewswire 4
simplywall.st 3
TradingView 2
Benzinga 2
MarketBeat 2
MSN 2

Event Lens

What the news is about

Classified themes
Deals and strategy 22
Market update 19
Earnings 14
Capital return 2
Analyst action 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Investing.com Nigeria Direct company coverage

Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com

This article reports on a Form 13D/A filing by XOMA Royalty Corp for July 16, 2026. The filing is a standard disclosure document related to equity ownership. The content primarily consists of navigational elements and market data, with the filing announcement being the central pi

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 02:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Ligand merger cashes out XOMA Royalty Corp (XOMA) director’s shares and options

XOMA Royalty Corp director Jack L. Wyszomierski reported the disposition of 21,828 common shares and the cancellation of all stock options due to XOMA's merger with Ligand Pharmaceuticals. Each share was converted into the right to receive $39.00 in cash plus contingent value rig

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 02:44
Source
Stock Titan
Stock Titan Direct company coverage

XOMA (XOMA) to redeem all preferred shares and issue CVRs ahead of Ligand deal

XOMA Royalty Corporation announced plans to redeem all outstanding Series A and Series B preferred shares on July 14, 2026, at $25.00 per share plus accrued dividends, ahead of its acquisition by Ligand Pharmaceuticals. The company also declared quarterly dividends for these pref

Tone
Positive 64/100
Event
Deals and strategy
Published
13 Jun 2026 00:40
Source
Stock Titan
GlobeNewswire Direct company coverage

XOMA Royalty Corporation Declares Quarterly Preferred Stock

XOMA Royalty Corporation announced cash dividends for its Series A and Series B Preferred Stockholders, with dividend payments scheduled for July 15, 2026. The company also declared its intention to redeem all outstanding shares of Preferred Stock on July 14, 2026, coinciding wit

Tone
Positive 72/100
Event
Capital return
Published
12 Jun 2026 20:10
Source
GlobeNewswire
Stock Titan Direct company coverage

XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition

XOMA Royalty Corporation has updated the structure of its acquisition by Ligand Pharmaceuticals by adding a new wholly-owned subsidiary, XOMA Royalty Holdings Corporation (HoldCo), to facilitate a holding company reorganization under Nevada law. This amendment to the merger agree

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 May 2026 13:09
Source
Stock Titan
TradingView Direct company coverage

Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake

Ligand Pharmaceuticals has announced a takeover plan for XOMA Royalty Corporation, acquiring a 47.0% stake through voting and support agreements. The deal, filed on May 1, 2026, involves Ligand purchasing XOMA for $39 per share in cash plus contingent value rights. This acquisiti

Tone
Positive 71/100
Event
Deals and strategy
Published
02 May 2026 01:10
Source
TradingView
Sahm Direct company coverage

This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday

Morgan Stanley analyst Sanjit Singh downgraded Appian Corp (APPN) from Overweight to Equal-Weight, cutting its price target from $41 to $25. Additionally, HC Wainwright & Co. analyst Joseph Pantginis downgraded XOMA Royalty Corp (XOMA) from Buy to Neutral with a $39 price target.

Tone
Neutral 50/100
Event
Analyst action
Published
01 May 2026 22:10
Source
Sahm
GlobeNewswire Direct company coverage

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm

The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of XOMA Royalty Corporation following the company's announcement of its acquisition by Ligand Pharmaceuticals for $739 million. Shareholders of XOMA are encouraged to partici

Tone
Neutral 50/100
Event
Deals and strategy
Published
28 Apr 2026 17:40
Source
GlobeNewswire